1. Oncocross’s CB Issuance: What Happened?
Oncocross announced on July 21, 2025, the issuance of ₩12.5 billion in convertible bonds (CBs) through a private placement. The conversion price is set at ₩11,436, with a minimum adjusted price of ₩8,006. The CBs carry a 0% coupon rate and a 2% maturity rate, with payment due on July 25, 2025.
2. Why the CB Issuance?
Oncocross, a biotech company specializing in AI-powered drug discovery platforms, has been experiencing net losses due to continuous R&D investments. The funds raised through this CB issuance will be used to strengthen R&D activities, accelerate drug development, and expand business operations. Given the current financial situation, securing external funding is crucial.
3. Impact on Stock Price?
- Positive Impacts: Increased R&D investment, accelerated drug development → enhanced growth potential. Increased market confidence due to institutional investor participation. Potential for short-term stock price increase.
- Negative Impacts: Potential stock dilution due to increased number of shares upon conversion. Increased financial burden from interest payments. Risk of stock price decline if R&D results are disappointing.
4. What Should Investors Do?
Oncocross’s CB issuance presents both opportunities and risks. Before making any investment decisions, investors should carefully analyze the current stock price, the planned use of funds from the CB issuance, the company’s R&D pipeline, competitor trends, and macroeconomic indicators. Consult with financial professionals and make informed decisions based on your individual investment goals and risk tolerance.
What are Oncocross’s Convertible Bonds?
Convertible bonds (CBs) are hybrid securities that act like bonds with interest payments but can be converted into company stock. Oncocross issued ₩12.5 billion in CBs to raise capital.
How will the CB issuance affect the stock price?
The CB issuance could lead to a short-term stock price increase, but there’s also a risk of a long-term decline due to stock dilution upon conversion.
Should I invest in Oncocross?
The decision to invest is ultimately yours. Carefully consider the positive and negative impacts of the CB issuance, the company’s fundamentals, and market conditions before making a decision.
Leave a Reply